[go: up one dir, main page]

HUP0300602A2 - A központi idegrendszerre ható diazabiciklusos hatóanyagok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk - Google Patents

A központi idegrendszerre ható diazabiciklusos hatóanyagok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk

Info

Publication number
HUP0300602A2
HUP0300602A2 HU0300602A HUP0300602A HUP0300602A2 HU P0300602 A2 HUP0300602 A2 HU P0300602A2 HU 0300602 A HU0300602 A HU 0300602A HU P0300602 A HUP0300602 A HU P0300602A HU P0300602 A2 HUP0300602 A2 HU P0300602A2
Authority
HU
Hungary
Prior art keywords
alkyl
group
alkoxy
ch2ch2
hydrogen atom
Prior art date
Application number
HU0300602A
Other languages
English (en)
Inventor
Anwer Basha
William H. Bunnelle
Jerome F. Daanen
Jianguo Ji
Jennifer M. Pace
Michael R. Schrimpf
Kevin B. Sippy
Karin R. Tietje
Richard B. Toupence
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/833,914 external-priority patent/US6809105B2/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of HUP0300602A2 publication Critical patent/HUP0300602A2/hu
Publication of HUP0300602A3 publication Critical patent/HUP0300602A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

A találmány (I) általános képletű N-szubsztituált diazabiciklusosvegyületek egy csoportjára valamint e vegyületek és e vegyületekettartalmazó gyógyszerkészítmények alkalmazásával neurotranszmitterekszelektív kibocsátásának szabályzására vonatkozik emlősben. Az (I)általános képletben A jelentése kovalens kötés, -CH2, -CH2CH2- vagy -CH2CH2CH2- csoport; B jelentése -CH2- vagy -CH2CH2-csoport, azzal amegkötéssel, hogy ha A jelentélse -CH2CH2CH2-, akkor B jelentése -CH2-csoport; Y jelentése kovalens kötés, -CH2 vagy -CH2CH2 csoport; Zjelentése kovalens kötés, -CH2- vagy -CH2CH2 csoport, azzal amegkötéssel, hogy ha Y jelentése -CH2CH2- csoport, akkor Z jelentésekovalens kötés; R1 jelentése az (X)-(XXV) általános képletű csoportokközül választható; R3 jelentése hidrogénatom, alkilcsoport vagyhalogénatom; R4 jelentése hidrogénatom, alkoxi-, alkil-, aminocsoport,halogénatom vagy nitrocsoport; R5 jelentése hidrogénatom, alkenil-,alkoxi-, alkoxi-alkoxi-, alkoxi-alkil-, alkoxi-karbonil-, alkoxi-karbonil-alkil-, alkil-, alkil-karbonil-, alkil-karbonil-oxi-, alkil-tio-, alkinil-, amino-, amino-alkil-, amino-karbonil-, amino-karbonil-alkil-, amino-szulfonil-, karboxil-, karboxi-alkil-, ciano-, ciano-alkil-, formil- formil-alkil-, halogénezett alkoxi-, halogénezettalkilcsoport, halogénatom, hidroxil-, hidroxi-alkil-, merkapto-,merkapto-alkil-, nitro-, 5-tetrazolil-csoport, -NR6S(O)2R7, -C(NR6)NR7R8, -CH2C(NR6)NR7R8, -C(NOR6)R7, -C(NCN)R6, -C(NNR6R7)R8, -S(O)2OR6 vagy -S(O)2R6 általános képletű csoport; R6, R7 és R8jelentése egymástól függetlenül hidrogénatom, vagy alkilcsoport; és R9jelentése hidrogénatom, alkoxi-karbonil-, alkil-, amino-, amino-alkil-, amino-karbonil-alkil-, benzil-oxi-karbonil-, ciano-alkil-,dihidro-3-piridinil-karbonil-, hidroxil-, hidroxi-alkil- vagy fenoxi-karbonil-csoport. Ó
HU0300602A 2000-04-27 2001-04-27 Diazabicyclic central nervous system active agents, pharmaceutical compositions containing them and their use HUP0300602A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55994300A 2000-04-27 2000-04-27
US09/833,914 US6809105B2 (en) 2000-04-27 2001-04-12 Diazabicyclic central nervous system active agents
PCT/US2001/013798 WO2001081347A2 (en) 2000-04-27 2001-04-27 Diazabicyclic central nervous system active agents

Publications (2)

Publication Number Publication Date
HUP0300602A2 true HUP0300602A2 (hu) 2003-06-28
HUP0300602A3 HUP0300602A3 (en) 2005-12-28

Family

ID=27072208

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300602A HUP0300602A3 (en) 2000-04-27 2001-04-27 Diazabicyclic central nervous system active agents, pharmaceutical compositions containing them and their use

Country Status (22)

Country Link
EP (3) EP2295437A1 (hu)
JP (2) JP4981232B2 (hu)
KR (4) KR100899950B1 (hu)
CN (3) CN100430398C (hu)
AR (1) AR030421A1 (hu)
AU (2) AU2001266559C1 (hu)
BG (2) BG66151B1 (hu)
BR (1) BR0107246A (hu)
CA (2) CA2407094C (hu)
CZ (4) CZ301324B6 (hu)
HK (1) HK1054375A1 (hu)
HU (1) HUP0300602A3 (hu)
IL (3) IL152231A0 (hu)
MX (1) MXPA02010594A (hu)
MY (3) MY137020A (hu)
NO (1) NO324250B1 (hu)
NZ (1) NZ521734A (hu)
PE (1) PE20011305A1 (hu)
PL (2) PL398491A1 (hu)
SK (2) SK287273B6 (hu)
TW (4) TW201141871A (hu)
WO (1) WO2001081347A2 (hu)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60037345T2 (de) 1999-12-10 2008-11-13 Pfizer Products Inc., Groton Pyrrolo(2,3-d)pyrimidin-Verbindungen
SE0100326D0 (sv) * 2001-02-02 2001-02-02 Astrazeneca Ab New compounds
CN101353321A (zh) * 2002-11-21 2009-01-28 辉瑞产品公司 3-氨基-哌啶衍生物及其制备方法
US20050261348A1 (en) * 2004-05-21 2005-11-24 Buckley Michael J (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
US20040242641A1 (en) * 2003-05-27 2004-12-02 Buckley Michael J. (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent
US7354937B2 (en) 2004-05-21 2008-04-08 Abbott Laboratories (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US20050065178A1 (en) * 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
US7399765B2 (en) 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
GB0322140D0 (en) * 2003-09-22 2003-10-22 Pfizer Ltd Combinations
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US20050171079A1 (en) 2004-02-04 2005-08-04 Schrimpf Michael R. Amino-substituted tricyclic derivatives and methods of use
EP1747206A1 (en) 2004-04-29 2007-01-31 Abbott Laboratories Amino-tetrazoles analogues and methods of use
US7351833B2 (en) 2004-07-23 2008-04-01 Abbott Laboratories (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate
KR20080080206A (ko) * 2005-12-20 2008-09-02 아스트라제네카 아베 Ｇａｂａａ-수용체 조절제로서의 치환된 신놀린 유도체 및그의 합성 방법
US20070184490A1 (en) * 2006-01-17 2007-08-09 Marleen Verlinden Neuronal nicotinic receptor ligands and their use
US7728031B2 (en) 2006-02-24 2010-06-01 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole derivatives
EP2255848A3 (en) 2006-09-04 2011-04-06 NeuroSearch AS Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
US8486979B2 (en) 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US8076350B2 (en) 2006-12-22 2011-12-13 Abbott Laboratories Spirocyclic azaadamantane derivatives and methods of use
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
ES2363998T3 (es) 2007-03-23 2011-08-22 Abbott Laboratories Derivados ester y carbamato de azaadamantano y métodos de uso de los mismos.
EP2188288A1 (en) 2007-09-11 2010-05-26 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole n-oxides
TW200932236A (en) 2007-10-31 2009-08-01 Janssen Pharmaceutica Nv Aryl-substituted bridged diamines as modulators of leukotriene A4 hydrolase
WO2009067586A1 (en) * 2007-11-21 2009-05-28 Abbott Laboratories Biaryl substituted diazabicycloalkane derivatives
BRPI0820668A2 (pt) 2007-12-07 2017-08-22 Abbott Gmbh & Co Kg Derivados de oxindol substituídos por 5-halogênio e seu uso para tratar doenças dependentes de vasopressina
CN101981027B (zh) 2007-12-07 2014-08-06 Abbvie德国有限责任两合公司 氨基甲基取代的羟吲哚衍生物及其用于治疗加压素依赖性疾病的用途
CN102026995B (zh) 2007-12-07 2014-10-29 Abbvie德国有限责任两合公司 5，6-二取代的羟吲哚衍生物和其用途
US8703774B2 (en) 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
JP5323088B2 (ja) 2007-12-18 2013-10-23 アクテリオン ファーマシューティカルズ リミテッド ５−アミノシクリルメチル−オキサゾリジン−２−オン誘導体
US7939527B2 (en) 2008-04-11 2011-05-10 Janssen Pharmaceutica Nv Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase
US8148408B2 (en) 2008-05-09 2012-04-03 Abbott Laboratories Selective substituted pyridine ligands for neuronal nicotinic receptors
WO2010111057A1 (en) * 2009-03-24 2010-09-30 Banyu Pharmaceutical Co., Ltd. Novel aminopyridine derivatives having aurora a selective inhibitory action
EP2430019B1 (en) 2009-05-14 2013-09-18 Janssen Pharmaceutica, N.V. Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene a4 hydrolase
WO2010138600A2 (en) 2009-05-29 2010-12-02 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
US8268853B2 (en) 2009-06-25 2012-09-18 Abbott Laboratories 3,9-diazaspiro[5,5]undecane amides and ureas and methods of use thereof
NZ598985A (en) 2009-09-04 2013-07-26 Biogen Idec Inc Bruton's tyrosine kinase inhibitors
US8680275B2 (en) 2009-10-23 2014-03-25 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
EP2491031B1 (en) * 2009-10-23 2013-08-07 Janssen Pharmaceutica N.V. Fused heterocyclic compounds as orexin receptor modulators
ME02437B (me) 2009-10-23 2016-09-20 Janssen Pharmaceutica Nv Disupstituirani oktahidropirolo[3,4-c]piroli kao modulatori oreksin receptora
US9586962B2 (en) 2011-04-20 2017-03-07 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
KR101655787B1 (ko) 2014-05-08 2016-09-22 대우조선해양 주식회사 선박의 하이브리드 공기조화시스템 및 그 방법, 그리고 이를 포함하는 선박 또는 해양구조물
KR20160021679A (ko) 2014-08-18 2016-02-26 대우조선해양 주식회사 극저온 환경의 장비용 히팅장치 및 방법 그리고 이를 구비하는 선박
US10000477B2 (en) 2014-10-31 2018-06-19 Indivior Uk Limited Dopamine D3 receptor antagonist compounds
IL288321B2 (en) 2016-03-10 2025-08-01 Janssen Pharmaceutica Nv Methods of treating depression using orexin-2 receptor antagonists
JP7214632B2 (ja) 2016-07-21 2023-01-30 バイオジェン エムエー インク． ブルトン型チロシンキナーゼ阻害剤のコハク酸塩形態および組成物
EP3686196B1 (en) * 2017-09-20 2024-06-12 Hangzhou Innogate Pharma Co., Ltd. Polycyclic compound acting as ido inhibitor and/or ido-hdac dual inhibitor
GB201809295D0 (en) 2018-06-06 2018-07-25 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
RS65638B1 (sr) 2018-11-14 2024-07-31 Janssen Pharmaceutica Nv Unapređene sintetičke metode pravljenja fuzionisanih heterocikličnih jedinjenja kao modulatora receptora oreksina
CN112010859B (zh) * 2019-05-30 2022-07-19 中国科学院上海药物研究所 一种并环化合物、其制备方法和用途
CN112047878B (zh) * 2020-10-15 2022-04-19 郑州猫眼农业科技有限公司 4-溴-6-氯吡啶-2-羧酸的制备方法
WO2024189472A1 (en) 2023-03-14 2024-09-19 Janssen Pharmaceutica Nv Improved synthetic methods of making substituted pyrimidine intermediates for synthesis of orexin receptor modulators

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0393424T3 (da) * 1989-04-17 1996-02-05 Bayer Ag Fremgangsmåde til fremstilling af 2,7-diazabicyclo(3.3.0)octaner
NL9201810A (nl) 1992-10-19 1994-05-16 Dsm Nv Werkwijze voor de omzetting van een olefine of een olefinemengsel.
CA2112165C (en) 1992-12-25 2003-04-08 Makoto Takemura Bicyclic amine derivatives
US5817679A (en) * 1993-04-01 1998-10-06 University Of Virginia 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands
US5478939A (en) * 1994-07-20 1995-12-26 American Cyanamid Company (R,R) and (S,S) 2,5-diazabicyclo [2,2,1]heptane derivatives
US5472958A (en) 1994-08-29 1995-12-05 Abbott Laboratories 2-((nitro)phenoxymethyl) heterocyclic compounds that enhance cognitive function
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
ATE200084T1 (de) * 1995-07-28 2001-04-15 Abbott Lab Furo-, thieno- und pyrrolopyridine und verwandte pyrinidin-, pyridazin- und triazinverbindungen verwendbar zur kontrolle von chemische synaptische übertragung
GB9519558D0 (en) * 1995-09-26 1995-11-29 Merck Sharp & Dohme Therapeutic agents
JPH09172344A (ja) 1995-12-19 1997-06-30 Murata Mfg Co Ltd 圧電共振子
US5733912A (en) 1997-02-19 1998-03-31 Abbott Laboratories 7A-heterocycle substituted hexahydro-1H-pyrrolizine compounds useful in controlling chemical synaptic transmission
WO1998054182A1 (en) * 1997-05-30 1998-12-03 Neurosearch A/S 9-AZABICYCLO(3.3.1)NON-2-ENE AND NONANE DERIVATIVES AS CHOLINERGIC LIGANDS AT NICOTINIC ACh RECEPTORS
SK284994B6 (sk) * 1997-05-30 2006-04-06 Neurosearch A/S Deriváty 8-azabicyklo[3.2.1]okt-2-énu, spôsob ich prípravy a ich použitie
GB9722343D0 (en) * 1997-10-22 1997-12-17 British Telecomm Distributed virtual environment
SK285198B6 (sk) * 1997-10-27 2006-08-03 Neurosearch A/S Homopiperazínový derivát, farmaceutická kompozícia obsahujúca tento derivát a jeho použitie
US6632823B1 (en) * 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
JP2002510690A (ja) * 1998-04-02 2002-04-09 アール・ジェイ・レイノルズ・タバコ・カンパニー アザトリシクロ［３．３．１．１］デカン誘導体とそれらを含有する薬剤組成物
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
JP2000026408A (ja) 1998-07-02 2000-01-25 Dai Ichi Seiyaku Co Ltd 対掌体的に純粋なピロリジン誘導体、その塩、それらの製造方法
US6804251B1 (en) 1998-11-12 2004-10-12 Broadcom Corporation System and method for multiplexing data from multiple sources
FR2786769B1 (fr) * 1998-12-04 2002-10-25 Synthelabo Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique
PT1147112E (pt) * 1999-01-29 2004-03-31 Abbott Lab Derivados diazabiciclicos como liganos nicotinicos do receptor de acetilcolina
EP1177196B1 (en) * 1999-05-04 2004-03-10 Neurosearch A/S Heteroaryl diazabicycloalkanes, their preparation and use
IL146476A0 (en) * 1999-05-21 2002-07-25 Abbott Lab Heterocyclic substituted aminoazacycles useful as central nervous system agents
AU1996301A (en) * 1999-12-14 2001-06-25 Neurosearch A/S Novel heteroaryl-diazabicycloalkanes

Also Published As

Publication number Publication date
KR100899950B1 (ko) 2009-05-28
AU2001266559B2 (en) 2005-03-03
TW201141871A (en) 2011-12-01
TWI311137B (en) 2009-06-21
HK1054375A1 (zh) 2003-11-28
KR20090071654A (ko) 2009-07-01
WO2001081347A2 (en) 2001-11-01
EP2298775A1 (en) 2011-03-23
CZ302038B6 (cs) 2010-09-15
SK287273B6 (sk) 2010-05-07
CA2407094A1 (en) 2001-11-01
SK287658B6 (sk) 2011-05-06
SK16812002A3 (sk) 2003-04-01
MY168244A (en) 2018-10-15
BG107303A (bg) 2003-07-31
KR20020093955A (ko) 2002-12-16
WO2001081347A3 (en) 2002-01-31
KR20090013833A (ko) 2009-02-05
CZ20023765A3 (cs) 2003-02-12
CN1440410A (zh) 2003-09-03
CA2407094C (en) 2009-11-17
MXPA02010594A (es) 2003-05-14
TWI323733B (en) 2010-04-21
HUP0300602A3 (en) 2005-12-28
TW200909432A (en) 2009-03-01
JP2012041349A (ja) 2012-03-01
TWI357903B (en) 2012-02-11
MY137020A (en) 2008-12-31
IL152231A0 (en) 2003-05-29
AR030421A1 (es) 2003-08-20
NO324250B1 (no) 2007-09-17
CA2683045A1 (en) 2001-11-01
CN101935322A (zh) 2011-01-05
NO20025107L (no) 2002-12-19
PE20011305A1 (es) 2001-12-31
JP4981232B2 (ja) 2012-07-18
AU6655901A (en) 2001-11-07
CN100430398C (zh) 2008-11-05
AU2001266559C1 (en) 2005-11-17
KR100947187B1 (ko) 2010-03-12
EP2295437A1 (en) 2011-03-16
IL203035A (en) 2010-12-30
PL398491A1 (pl) 2012-06-04
KR100947188B1 (ko) 2010-03-12
PL358340A1 (en) 2004-08-09
BG110620A (bg) 2010-07-30
MY145722A (en) 2012-03-30
NZ521734A (en) 2004-10-29
CZ302795B6 (cs) 2011-11-16
IL177316A0 (en) 2006-12-10
TW200617013A (en) 2006-06-01
NO20025107D0 (no) 2002-10-24
BR0107246A (pt) 2002-10-01
KR20090121385A (ko) 2009-11-25
BG66151B1 (bg) 2011-08-31
KR100961406B1 (ko) 2010-06-09
IL177316A (en) 2010-06-30
CN102863441A (zh) 2013-01-09
JP2003531210A (ja) 2003-10-21
CZ301324B6 (cs) 2010-01-13
EP1284976A2 (en) 2003-02-26
CZ302072B6 (cs) 2010-09-29

Similar Documents

Publication Publication Date Title
HUP0300602A2 (hu) A központi idegrendszerre ható diazabiciklusos hatóanyagok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
DE69416869D1 (de) Diazabicyclische neurokinin antagonisten
AP2001002088A0 (en) 4,4-Biarylpiperidine derivatives with opiod receptor activity.
NL350077I2 (nl) Cyprosulfamide
BG106586A (en) Pyrazolopyramidines as therapeutic agents
MXPA02012425A (es) Compuestos nuevos.
EE200100350A (et) Fenüülfenantridiinid, nende kasutamine ravimite valmistamiseks ning neid sisaldav ravim
SE0003984L (sv) Adenosin A3-receptormodulatorer
TR199700550A2 (xx) S�lfonamidler ve kullan�mlar�.
MY127144A (en) New anticholinergics which may be used as medicaments as well as processes for preparing them
AR022860A1 (es) Derivados de camptotecina que poseen actividad antitumoral
GEP20074210B (en) Tropane derivatives as ccr5 modulators
MY121294A (en) Novel hexanoic acid derivatives.
TR200101507T2 (tr) Geniş antibakteriyel spektrumu olan imidazo[4,5-b] piridinyummetil-içerikli sefem bileşimleri
CA2381819A1 (en) New benzimidazolone derivatives having mixed serotonine and dopamine receptors affinity
SE0202133D0 (sv) Novel compounds
TR199901904T2 (xx) 3-piridil enantiyomerleri ve bunlar�n analjezik olarak kullan�lmas�.
SE9702564D0 (sv) New compounds
BRPI0614493B8 (pt) uso de um composto derivado de quinolina, sua combinação, composição farmacêutica, uso da referida combinação, produto, processo para a preparação de um composto e o referido composto
BG105728A (en) USE OF PYRIDAZINO[4,5-b]INDOLE-1-ACETAMIDE DERIVATIVES FOR PREPARING MEDICINES FOR TREATING DISEASES RELATED TO THE DYSFUNCTION OF PERIPHERAL BENZODIAZEPIN RECEPTORS
ATE439363T1 (de) Imidazo 2,1-b -1,3,4-thiadiazole sulfonamides
HUP0001923A1 (hu) Peszticid hatású 1-aril-3-imino-pirazolok, eljárás előállításukra és alkalmazásuk
BRPI0608216A2 (pt) agente terapêutico para um tumor, método para tratar um tumor, e, uso de um composto de benzoìla, uma pró-groga do mesmo ou um sal farmaceuticamente aceitável do mesmo
TW200740781A (en) Novel compounds
TR200102481T2 (tr) Fazlı zincir muadili içeren 2-aminopiridinler.

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: ABBVIE INC., US

Free format text: FORMER OWNER(S): ABBOTT LABORATORIES, US

FD9A Lapse of provisional protection due to non-payment of fees